Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985192 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00985192 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 49 participants.
The verdict
NCT00985192, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985192
The ClinicalTrials.gov registry entry for NCT00985192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00985192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00985192 about?
NCT00985192 is a clinical study titled "Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophag...
What is the current status of trial NCT00985192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2009-09. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00985192?
The interventions under investigation include: laboratory biomarker analysis (OTHER), everolimus (DRUG).
Who is sponsoring clinical trial NCT00985192?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.